Breast Cancer Polygenic Risk Score Validation and Effects of Variable Imputation

Author:

Beck Jeffrey J.1ORCID,Slunecka John L.1,Johnson Brandon N.1,Van Asselt Austin J.1,Finnicum Casey T.1,Ageton Cheryl2,Krie Amy2,Nickles Heidi2ORCID,Cowan Kenneth3,Maxwell Jessica3,Boomsma Dorret I.4ORCID,de Geus Eco4ORCID,Ehli Erik A.1ORCID,Hottenga Jouke-Jan4ORCID

Affiliation:

1. Avera Genetics, Avera McKennan Hospital & University Health Center, Sioux Falls, SD 57105, USA

2. Avera Cancer Institute, Sioux Falls, SD 57105, USA

3. Fred and Pamela Buffet Cancer Center and Eppley Institute for Research in Cancer at University of Nebraska Medical Center, Omaha, NE 68105, USA

4. Department of Biological Psychology, Netherlands Twin Register, Vrije Universiteit Amsterdam, 1081 BT Amsterdam, The Netherlands

Abstract

Breast cancer (BC) is a complex disease affecting one in eight women in the USA. Advances in population genomics have led to the development of polygenic risk scores (PRSs) with the potential to augment current risk models, but replication is often limited. We evaluated 2 robust PRSs with 313 and 3820 SNPs and the effects of multiple genotype imputation replications in BC cases and control populations. Biological samples from BC cases and cancer-free controls were drawn from three European ancestry cohorts. Genotyping on the Illumina Global Screening Array was followed by stringent quality control measures and 20 genotype imputation replications. A total of 468 unrelated cases and 4337 controls were scored, revealing significant differences in mean PRS percentiles between cases and controls (p < 0.001) for both SNP sets (313-SNP PRS: 52.81 and 48.07; 3820-SNP PRS: 55.45 and 49.81), with receiver operating characteristic curve analysis showing area under the curve values of 0.596 and 0.603 for the 313-SNP and 3820-SNP PRS, respectively. PRS fluctuations (from ~2–3% up to 9%) emerged across imputation iterations. Our study robustly reaffirms the predictive capacity of PRSs for BC by replicating their performance in an independent BC population and showcases the need to average imputed scores for reliable outcomes.

Funder

US National Institute for Mental Health

Dutch Research Council

Fred & Pamela Buffet Cancer Center and National Cancer Institute

Publisher

MDPI AG

Reference32 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA A Cancer J. Clin.,2021

2. National Center for Health Statistics (US) (2021). Table 5, Age-adjusted death rates for selected causes of death, by sex, race, and Hispanic origin: United States, selected years 1950–2018, Health, United States, 2019 [Internet].

3. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement;Siu;Ann. Intern. Med.,2016

4. (2023, November 10). Key Statistics for Breast Cancer. Available online: https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html.

5. The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up;Sankatsing;Int. J. Cancer,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3